11/21/2016 11:25:23 AM
CORAL GABLES, Fla., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:
CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for
people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer,
and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will participate as part of the
Underdiscovered Neuro-Innovators Panel at the 28th Annual Piper Jaffray Healthcare Conference being
held at Lotte New York Palace, NY, November 29-30. The panel will take place Tuesday, November 29 at
10 am EST.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder.
Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food
and Drug Administration (FDA) and orphan drug designation for LEMS, CMS and myasthenia gravis.
Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette's Disorder.
CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by
the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West
Syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril®
comments powered by